SAR408701

Unassigned

New Medicines

Non-squamous non-small cell lung cancer (NSCLC) expressing CEACAM5 - second/third-line

Information

New molecular entity
Sanofi
Sanofi

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Monoclonal antibody-drug conjugate comprising of an anti-CEACAM5 antibody covalently bound to DM4 (an antimitotic agent) through a cleavable SPDB linker [N-succinimidyl 4-(2-pyridyldithio)-butyrate
There were 46,403 new cases of lung cancer diagnosed in the UK in 2014. NSCLC accounts for 85% of cases of lung cancer. The NSCLCs are often grouped together when treatment is being considered. 42% are squamous [1].
Non-squamous non-small cell lung cancer (NSCLC) expressing CEACAM5 - second/third-line
Intravenous infusion